← Human Trials & Peer-Reviewed Studies
Addition of growth hormone to the microflare stimulation protocol among women with poor ovarian response.
Plain-language guide to PMID 26381201 (2015): open-label randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 26381201
- Journal
- International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
- Year
- 2015
- Study type
- Randomized Controlled Trial
- Authors
- Bayoumi YA et al. (4 authors)
- DOI
- 10.1016/j.ijgo.2015.05.034
- Registered trial
- NCT02185326
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.
Who Took Part
By PubMed's age tags, the people studied were adults, women only.
A parallel, open-label, randomized controlled trial was conducted among patients with poor ovarian response who attended a center in Cairo, Egypt, between July 10 and December 31, 2014.
Participants were randomly assigned using a computer program (random block size of 4-8) to undergo the microflare protocol with or without GH.
How the Study Was Run
The design is described as randomized, open-label and parallel-group.
Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.
Being open-label, the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study did not mask who received what.
The Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group ran side by side rather than switching.
Primary outcomes were the mean numbers of mature oocytes retrieved and fertilized.
Analyses were done per protocol: women with cycle cancellations were excluded.
What Was Measured
PubMed files the paper under topics including Egypt, Fertilization in Vitro, Growth Hormone, Oocytes and Ovulation Induction.
The authors tagged it with the keywords In vitro fertilization, Intracytoplasmic sperm injection, Microflare stimulation protocol, Poor ovarian reserve, Poor ovarian response and Poor responders.
What This Means in Plain Language
The paper is a randomized, open-label and parallel-group study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2015 (International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.